Clinical Trial Update: A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing sunitinib to placebo in patients at high risk of recurrent renal cell cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Neoplasms
• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Kidney Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2017-08-18